| From: jmhollen | 7/18/2006 3:10:51 PM | | | | | | NanoViricides Achieving Recognition in the Biotech and Nanotech Industries for Its Nanotechnology-based Anti-viral Therapies
WEST HAVEN, Conn., Jul 18, 2006 (BUSINESS WIRE) -- NanoViricides, Inc. (Pink Sheets:NNVC) announced today that two of its senior executives, Dr. Anil Diwan, Chairman and President, and Dr. Eugene Seymour, CEO, have been invited to lecture and present the NanoViricides at five different conferences over the next five months. Dr. Diwan will be presenting at four nanotechnology conferences in the United States and Dr. Seymour at an international nanomedicine conference in London.
Dr. Anil Diwan, Chairman and President, said, "For many years it has been believed that the technologies inherent in the nanomedicine approach would result in far superior drugs than anything presently existing. We feel that we're at the forefront in this arena. We believe that with the first viruses we have targeted, avian flu (H5N1) and common influenza (H1N1), we have achieved results in the preclinical studies far superior to any existing drug. NanoViricides, Inc. is awaiting permission from the appropriate institutions to release the results."
In other news, the company announced that they are working with their auditors to complete the June 30, 2006 audit, and the company expects the company's financials to be released over the coming weeks. The company aims to file with the SEC to become a fully reporting company after the audit is completed.
Dr. Eugene Seymour, CEO, further added, "We believe that our business plan is sound. Just yesterday the Financial Times had as its lead story that Citigroup is expanding its research and its Director of Investment Research said 'the most important task for analysts was to produce quality research, such as thematic reports on bird flu ...'". Dr Seymour continued, "NanoViricides at this time is strong. We have over $2,000,000 cash on hand. We have a strong drug pipeline with industry-leading drugs against highly pathogenic bird flu and common influenza in preclinical studies, and an anti-rabies drug in development. I see no technological barriers to accomplish our stated goals to develop additional new drugs in the areas of HIV, Hepatitis C as well as other viral infections in 2007 and beyond."
About NanoViricides - nanoviricides.com
SOURCE: NanoViricides, Inc.
CONTACT: NanoViricides, Inc. Leo Ehrlich, 917-853-6440 leo@nanoviricides.com
. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: jmhollen who wrote (1328) | 7/18/2006 7:39:57 PM | | From: donpat | | | | | Looks like Citigroup MAY be involved in analyzing NanoViricides - it's where the future of medicine lies - the money is available for such worthy efforts as bird flu R&D I'm sure. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: donpat | 7/25/2006 2:19:07 PM | | | | | | SoluBest/Of Interest/For the record
solubest.com
Recent US Patent:
United States Patent 7,081,450
Goldshtein July 25, 2006
Water soluble nanoparticles of hydrophilic and hydrophobic active materials and an apparatus and method for their production
Abstract
This invention provides a soluble nano-sized particles formed of a core (water-insoluble lipophilic compound or hydrophilic compound) and an amphiphilic polymer and which demonstrated improved solubility and/or stability. The lipophilic compound within the soluble nano-sized soluble ("solu-nanoparticles") may consist of pharmaceutical compounds, food additives, cosmetics, agricultural products and veterinary products. The invention also provides novel methods for preparing the nano-sized soluble particles, as well as a novel chemical reactor for manufacturing an inclusion complex comprising the nano-sized soluble particles.
Inventors: Goldshtein; Rina (Har Hebron, IL)
Assignee: Solubest Ltd. (Ness Ziona, IL)
Appl. No.: 256023
Filed: September 26, 2002
patft.uspto.gov |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: donpat | 7/25/2006 2:42:38 PM | | | | | | A Dual Ligand Approach for Enhancing Targeting Selectivity of Therapeutic Nanocarriers
One of the advantages of using nanoparticles as delivery devices for therapeutic and imaging agents is the ability to attach a wide variety of tumor-targeting molecules to the nanoparticle surface. Typically, these molecules target cell-surface receptors that tumor cells overexpress, but that are nonetheless present at some level on many healthy cells, too, and thus such targeting strategies can still result in potent drugs reaching non-malignant cells.
To overcome this less-than-perfect tumor targeting, a team of investigators led by Ravi Ballamkonda, Ph.D., decided to take advantage of the fact that tumors usually overexpress more than one cell-surface receptor. By targeting two such receptors simultaneously, using two targeting molecules on the same nanoparticle, the researchers were able to completely spare non-targeted cells while delivering an effective therapeutic dose of doxorubicin to tumor cells. The results of this study appear in the Journal of Controlled Release.
As a proof-of-concept model, the researchers created doxorubicin-loaded nanoparticles targeted with folic acid and a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR); many types of tumor cells overexpress folic acid and EGFR. To determine the optimal ratio of target molecules, the investigators created a series of nanoparticles with a constant number of antibodies but with various amounts of folic acid. The investigators also created identical nanoparticles targeted with only folic acid or the EGFR antibody.
Administering these nanoparticles to tumor cells and healthy cells growing in culture showed that, as expected, the singly targeted nanoparticles killed tumor cells but also a percentage of healthy cells. In contrast, the dual-labeled nanoparticles were at worst, less toxic to healthy cells, and at best non-toxic to healthy cells while retaining full toxicity for tumor cells. The researchers determined that the optimal formulation contained three monoclonal antibodies and an average of 200 folic acid molecules per nanoparticle.
This work is detailed in a paper titled, “A dual ligand approach for enhancing targeting selectivity of therapeutic nanocarriers.” Investigators from Case Western Reserve University and the University of Texas at Houston also participated in this study. This paper was posted online in advance of print publication. An abstract is available at the journal’s website. View abstract[ sciencedirect.com ].
nano.cancer.gov
Posted 25th July 2006
azonano.com |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: donpat | 8/1/2006 8:47:23 AM | | | | | | Magnetic Nanocapsules for Smart Drug Delivery
By combining peptide-based polymers with modified iron oxide nanoparticles, researchers at the Centre National de la Recherche Scientifique in Pessac, France, have developed nanoparticles that can be manipulated in a magnetic field and that can respond to changes in pH and other physiologic stimuli.
These nanoparticles, which can be modified to include targeting molecules, could serve as a versatile, smart platform for delivering drugs and imaging agents to tumors.
Writing in the journal Progress in Solid State Chemistry, Sébastien Lecommandoux, Ph.D., and his colleagues describe their use of what are called diblock copolymers, made of peptides to create stimuli-responsive nanoparticles. The investigators make these polymers by first stringing together short stretches of single amino acids to form peptide blocks.
They then link two of these blocks together in an alternating pattern to create the diblock copolymer. Through the careful choice of the amino acid constituents, and hence the two blocks, that go into a polymer the investigators are able create nanoparticles that can respond to a wide range of conditions.
When the investigators mixed the diblock copolymers with iron oxide nanoparticles modified to be compatible with either water or organic solvents, the components self-assemble into stable nanoparticles. Depending on the choice of polymer and the form of iron oxide used, the resulting nanoparticles are either hollow or have a core-shell structure.
The investigators note that the conditions they used to prepare these various nanoparticles are amenable for encapsulating drug molecules, too. They also comment that they can deform these nanoparticles by changing pH and applying a magnetic field, an event that would release entrapped drug.
This work is detailed in a paper titled, “Smart hybrid magnetic self-assembled micelles and hollow capsules.” An abstract of this paper is available at the journal’s website [http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TX3-4J4HK73-4&_user=10&_handle=V-WA-A-W-WA-MsSAYWA-UUA-U-AACCDUCDUA-AACBWYZCUA-VCZVAZW-WA-U&_fmt=summary&_coverDate=07%2F31%2F2006&_rdoc=11&_orig=browse&_srch=%23toc%235579%232006%23999659997%23625204!&_cdi=5579&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=ad2943089b96c3c29d8bcf7a0e947fbb ].
Source: National Cancer Institute
physorg.com |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: donpat who wrote (1334) | 8/2/2006 7:54:24 AM | | From: xcentral1 | | | | NNVC -- NanoViricides, Inc.
Com ($0.001)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
NanoViricides, Inc. Preparing to Release Financials and File With SEC
WEST HAVEN, Conn., Aug 01, 2006 (BUSINESS WIRE) -- NanoViricides, Inc. (Pink Sheets:NNVC), announced today that it is very close to releasing the financial data for the June 30, 2006 year end.
The Company's CEO, Eugene Seymour, MD, MPH stated, "the Company has received numerous inquiries from its stockholders and others as to when we will release our financial data and complete the SEC filing to become a fully reporting company. We are now very close to accomplishing both of these objectives."
The Company also updated its shareholders as to the status of its financial audit. Mr. Leo Ehrlich, CFO, announced that "the Company's financial statements for our fiscal year end, June 30, 2006, have already been forwarded to our auditors, Holtz Rubenstein Reminick LLP. The auditors have sent out the confirmation requests and the audit review is in progress. We are now preparing for releasing the financials after a preliminary approval by the auditors."
The Company had intended to file with the SEC in 2005; however a discrepancy was found in the number of common stock shares claimed by certain earlier stockholders, resulting in a delay.
"The Company took decisive action and had the shares in question canceled, an outcome with a significant benefit to our shareholders. We are now focused on becoming an SEC reporting company," Mr. Ehrlich added further.
Mr. Ehrlich, continued, "In this week's edition of Barron's, there appears an interview with Dean LeBaron, Chairman of Virtualquest. Mr. LeBaron comments that 'Bird flu is likely to arrive in the United States before the end of the year' and on another question responds 'essentially we are very close to the breaking point where there is a particular class and set of drugs that will deliver individually targeted treatments and hopefully will revolutionize medicine.' I believe his opinions are representative of a significant number of fund managers. Once we become a reporting company, NanoViricides stock will be available for investment to a huge pool of potential new stockholders, including funds and institutional investors. This will help in funding the Company's facilities and drug development activities."
The Company continues to receive a number of questions from its stockholders at our email info@nanoviricides.com. We will attempt to answer them in forthcoming press releases. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: xcentral1 who wrote (1335) | 8/2/2006 7:59:45 AM | | From: xcentral1 | | | | I also reached out asking about the Time Line that is on the website.... :
<<On the NNVC website is a "Time Line" for your products.
This Time Line was published long before the latest rounds of successful tests, related results and the Vietnam experience.
Question = How have these new developments affected those published projections?
.... And is there any chance for a "fast track" special situation for expediting any of these products?.... >>
<<In terms of developing the actual drugs for influenza and bird flu we are ahead of our expectations. We now need to become a reporting company which will allow us to work with major bankers who have expressed interest; and begin the construction of a GMP level facility in order to make materials for Phase 1 tests. Certain FDA requirements were changed during the year which now require these testing materials be produced under GMP. On the positive side, the urgent need of a drug like Aviflucide is so needed, that the FDA approval process is possible to be fast tracked. All this assumes that the drug meets FDA approval for phase 1 testing, which at this time we believe will be met but can not assure you that it will.
I hope this answers your question.>>
Cool huh!!! |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |
